Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.

Liu, Fengjun

Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. [electronic resource] - Cancer science Oct 2008 - 2055-61 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1349-7006

10.1111/j.1349-7006.2008.00905.x doi


Animals
Antibiotics, Antineoplastic--pharmacology
Antisense Elements (Genetics)--genetics
Apoptosis--drug effects
Carcinoma, Hepatocellular--blood supply
Cell Line, Tumor
Cell Proliferation--drug effects
Doxorubicin--pharmacology
Gene Expression Regulation, Neoplastic--drug effects
Gene Transfer Techniques
Genetic Therapy--methods
Humans
Hypoxia-Inducible Factor 1, alpha Subunit--genetics
Immunohistochemistry
Ki-67 Antigen--metabolism
Liver Neoplasms, Experimental--blood supply
Male
Mice
Mice, Nude
Neovascularization, Pathologic--drug therapy
Proliferating Cell Nuclear Antigen--metabolism
Vascular Endothelial Growth Factor A--metabolism
Xenograft Model Antitumor Assays